&nbsp;

Drugs Used:

bortezomib (PDRP prior authorization),

lenalidomide,

dexamethasone

Quick Link(s):

Regimen Monograph

Dec 2023

Drug

binimetinib

Other Name(s): Mektovi®

Quick Link(s):

Drug Monograph, Patient Info Sheet

Jul 2023

Regimen

BEVA+PEMB(MNT)

Cancer Type:

Gynecologic,

Cervix

Intent: Palliative

Funding:

New Drug Funding Program

Pembrolizumab - Metastatic, Persistent, or Recurrent Carcinoma of the Cervix

New Drug Funding Program

Bevacizumab (Biosimilar) - Metastatic (Stage IVB), Persistent, or Recurrent Carcinoma of the Cervix

Drugs Used:

pembrolizumab,

bevacizumab

Quick Link(s):

Regimen Monograph

Nov 2023

Regimen

BEACOPDAC(ESC)

Cancer Type:

Hematologic,

Lymphoma - Hodgkin

Intent: Curative

Funding:

ODB - General Benefit

prednisone

Drugs Used:

Quick Link(s):

Regimen Monograph

Aug 2023

Regimen

BEACOPDAC-14

Cancer Type:

Hematologic,

Lymphoma - Hodgkin

Intent: Curative

Funding:

ODB - General Benefit

prednisone

Drugs Used:

Quick Link(s):

Regimen Monograph

Aug 2023

Regimen

BORTDEXALENA(LD)

Cancer Type:

Hematologic,

Multiple Myeloma

Intent: Palliative

Funding:

New Drug Funding Program

Bortezomib - In Combination with Lenalidomide and Dexamethasone for Previously Untreated Multiple Myeloma Pre-SCT

ODB Limited Use

lenalidomide - Induction therapy for transplant eligible, newly diagnosed multiple myeloma, according to clinical criteria

ODB - General Benefit

dexamethasone

Drugs Used:

Quick Link(s):

Regimen Monograph

Dec 2023

Regimen

BINIENCO

Cancer Type:

Lung,

Non-Small Cell

Intent: Palliative

Drugs Used:

binimetinib (Unfunded),

encorafenib (Unfunded)

Quick Link(s):

Regimen Monograph

Feb 2025

Regimen

BORTDEXAPOMA

Cancer Type:

Hematologic,

Multiple Myeloma

Intent: Palliative

Funding:

New Drug Funding Program

Bortezomib - In Combination with Pomalidomide and Dexamethasone for Previously Treated Multiple Myeloma

ODB - General Benefit

dexamethasone

Exceptional Access Program

pomalidomide - For patients with relapsed and/or refractory multiple myeloma, according to specific criteria

Drugs Used:

Quick Link(s):

Regimen Monograph

Mar 2025

Regimen

BORTDEXALENA+DARA; LENA+DARA(MNT)

Cancer Type:

Hematologic,

Multiple Myeloma

Intent: Palliative

Funding:

New Drug Funding Program

Bortezomib - Previously Untreated - Multiple Myeloma Pre-Stem Cell Transplant

ODB - General Benefit

dexamethasone

Drugs Used:

daratumumab (Unfunded),

bortezomib (Unfunded),

lenalidomide (Unfunded),

dexamethasone

Quick Link(s):

Regimen Monograph

Updated

Apr 2025

Regimen

BELZ

Cancer Type:

Endocrine,

Pancreatic Neuroendocrine,

Genitourinary,

Renal cell / Kidney

Intent: Curative, Palliative

Funding:

Exceptional Access Program

Belzutifan – For the treatment of adult patients with von Hippel-Lindau (vHL) disease, based on criteria

Drugs Used:

belzutifan